Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Carbapenem Antibiotic | Research

An analysis of differences in Carbapenem-resistant Enterobacterales in different regions: a multicenter cross-sectional study

Authors: Bo Guo, Peili Li, Bingyu Qin, Shanmei Wang, Wenxiao Zhang, Yuan Shi, Jianxu Yang, Jingjing Niu, Shifeng Chen, Xiao Chen, Lin Cui, Qizhi Fu, Lin Guo, Zhe Hou, Hua Li, Xiaohui Li, Ruifang Liu, Xiaojun Liu, Zhengrong Mao, Xingguo Niu, Chao Qin, Xianrong Song, Rongqing Sun, Tongwen Sun, Daoxie Wang, Yong Wang, Lanjuan Xu, Xin Xu, Yuejie Yang, Baoquan Zhang, Dongmin Zhou, Zhaozhen Li, Yinyin Chen, Yue Jin, Juan Du, Huanzhang Shao

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Objective

This study aimed to explore the characteristics of carbapenem-resistant Enterobacterales (CRE) patients in the intensive care unit (ICU) in different regions of Henan Province to provide evidence for the targeted prevention and treatment of CRE.

Methods

This was a cross-sectional study. CRE screening was conducted in the ICUs of 78 hospitals in Henan Province, China, on March 10, 2021. The patients were divided into provincial capital hospitals and nonprovincial capital hospitals for comparative analysis.

Results

This study involved 1009 patients in total, of whom 241 were CRE-positive patients, 92 were in the provincial capital hospital and 149 were in the nonprovincial capital hospital. Provincial capital hospitals had a higher rate of CRE positivity, and there was a significant difference in the rate of CRE positivity between the two groups. The body temperature; immunosuppressed state; transfer from the ICU to other hospitals; and use of enemas, arterial catheters, carbapenems, or tigecycline at the provincial capital hospital were greater than those at the nonprovincial capital hospital (P < 0.05). However, there was no significant difference in the distribution of carbapenemase strains or enzymes between the two groups.

Conclusions

The detection rate of CRE was significantly greater in provincial capital hospitals than in nonprovincial capital hospitals. The source of the patients, invasive procedures, and use of advanced antibiotics may account for the differences. Carbapenem-resistant Klebsiella pneumoniae (CR-KPN) was the most prevalent strain. Klebsiella pneumoniae carbapenemase (KPC) was the predominant carbapenemase enzyme. The distributions of carbapenemase strains and enzymes were similar in different regions.
Literature
23.
go back to reference Lin Q, Wu M, Yu H, et al. Clinical and microbiological characterization of carbapenem-resistant enterobacteriales: a prospective cohort study. Front Pharmacol. 2021;12:716324.CrossRefPubMedPubMedCentral Lin Q, Wu M, Yu H, et al. Clinical and microbiological characterization of carbapenem-resistant enterobacteriales: a prospective cohort study. Front Pharmacol. 2021;12:716324.CrossRefPubMedPubMedCentral
Metadata
Title
An analysis of differences in Carbapenem-resistant Enterobacterales in different regions: a multicenter cross-sectional study
Authors
Bo Guo
Peili Li
Bingyu Qin
Shanmei Wang
Wenxiao Zhang
Yuan Shi
Jianxu Yang
Jingjing Niu
Shifeng Chen
Xiao Chen
Lin Cui
Qizhi Fu
Lin Guo
Zhe Hou
Hua Li
Xiaohui Li
Ruifang Liu
Xiaojun Liu
Zhengrong Mao
Xingguo Niu
Chao Qin
Xianrong Song
Rongqing Sun
Tongwen Sun
Daoxie Wang
Yong Wang
Lanjuan Xu
Xin Xu
Yuejie Yang
Baoquan Zhang
Dongmin Zhou
Zhaozhen Li
Yinyin Chen
Yue Jin
Juan Du
Huanzhang Shao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09005-9

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine